BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06251310 (SW-682 in Advanced Solid Tumors): BVCT ex-ante prediction vs. reported outcome

On 4 Nov 2024, BioinvestGPT's BVCT predicted technical partial success and commercial failure for this trial. The 6 Mar 2025 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically probably insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT06251310
Drug Name
SW-682
Drug MoA
pan-TEAD inhibitor
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
Advanced Solid Tumors
Human Patients
186
Sponsor
SpringWorks Therapeutics
Phase
Phase 1

Prediction of , index 1825

Prospective Prediction
Prediction Index
1825
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient (additive) clinical benefit in OS)
Technical Prediction
partial SUCCESS (statistically maybe significant yet weak (additive) clinical benefit in ORR/PFS)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
122 days in advance
Readout Data Interpretation
SW-682's further development has been discontinued probably due to insufficient clinical benefit
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically probably insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 1a/1b Dose Escalation, Dose Expansion Study of SW-682 in Participants With Advanced Solid Tumors Enriched for Those With Hippo Pathway Mutations
Phase
Phase 1
Status
Recruiting
Enrollment
186
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Conditions
Advanced Solid Tumor; Mesothelioma, Malignant
Interventions
DRUG: SW-682; DRUG: Combination Therapy
Design
Non randomized · Sequential · None
Primary purpose
Treatment
Start
2024-07-31
Primary completion
2027-01-18
Completion
2027-01-18
Primary outcomes
  • Incidence of Adverse Events (Part 1 Only) (Up to 24 months)
  • Maximum Tolerated Dose (Part 1 Only) (Up to 24 months)
  • Recommended Dose for Expansion (Part 1 Only) (Up to 24 months)
  • Objective Response Rate (Part 2 Only) (Up to 24 months)

NCT06251310 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials